Health and Pharma’s Post

Pfizer announced significant findings from its Phase 3 #ECHELON-3 trial, showing that #Adcetris® (#brentuximab vedotin)in combination with #lenalidomide and #rituximab markedly enhances survival rates for patients with relapsed/refractory diffuse large B-cell #lymphoma (#DLBCL) over standard care. This landmark achievement promises new treatment possibilities for patients battling this aggressive form of #cancer. Dr. Roger Dansey, Pfizer’s Chief Development Officer for #Oncology, emphasized the significance of these results, stating, “This is the third Phase 3 study in a type of lymphoma to demonstrate an overall survival benefit for an Adcetris combination. Based on the strong results from ECHELON-3, we’re excited that Adcetris could address an area of high unmet need in patients with relapsed or refractory DLBCL irrespective of CD30 expression. The results are particularly encouraging because the study evaluated heavily pre-treated patients, including some who received prior CAR-T therapy.” https://lnkd.in/db6hUJ2N

Compared with the pembrolizumab combination, tiragolumab-based treatment did not show improvements in PFS (HR, 1.27; 95% CI, 1.02-1.57) or OS (HR, 1.33; 95% CI, 1.02-1.73) across the intent-to-treat population. https://lnkd.in/eEFCycyj #NSCLC #cancer #oncology

Exciting news in oncology! The FDA has approved Lymphir (denileukin diftitox-cxdl), a groundbreaking immunotherapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL). As the only therapy targeting IL-2 receptors in malignant T-cells and Tregs, it offers new hope for patients battling this challenging disease. Read more here: https://lnkd.in/e4aPYgup #Oncology #FDAApproval #CTCL #Immunotherapy #HealthcareInnovation #PharmacyNews

Imugene Limited (ASX:IMU, OTC:IUGNF) is trading higher on achieving the holy grail in #cancer treatment of #CompleteResponse in three patients who had previously experienced a return of their cancer following autologous CAR T therapy. A complete response means that the cancer has not returned. Shares have been as much as 30.65% higher in ASX trading intra-day to A$0.081. Results come from the company’s ongoing Phase 1b clinical trial of azer-cel (azercabtagene zapreleucel), an allogeneic off-the-shelf CD19 CAR T-cell therapy, in patients with relapsed or refractory diffuse large B-cell #lymphoma (DLBCL), a type of non-Hodgkin’s lymphoma (NHL). More at #Proactive #ProactiveInvestors #Biotech #Biopharmaceutcials #Oncology #CellTherapy http://ow.ly/Oree105Ho06

Researchers at the US National Cancer Institute (NCI) have developed a targeted, chemotherapy-free treatment regimen that leads to lasting remissions in people with certain types of diffuse large B-cell lymphoma (DLBCL). The regimen called ViPOR includes five drugs: venetoclax, ibrutinib, prednisone, obinutuzumab and lenalidomide. These drugs act synergistically on several molecular pathways essential for DLBCL survival. The study demonstrated that ViPOR is curative in a significant number of patients with DLBCL, representing an important conceptual shift in the treatment of this disease. #clinicaltrials https://lnkd.in/dQ-KA_uc

We’re making significant progress in the fight against #lungcancer. Today at #ASCO24, we shared important results from our Phase 3 clinical trial evaluating treatments for patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). After five years of median follow-up, one of our treatments showed unprecedented progression-free survival, with 60% of patients alive without disease worsening.   Lung cancer is the #1 cause of cancer-related death around the world. We have spent years at Pfizer working on developing potential solutions that can help people with cancer live better and longer lives. These results represent Pfizer’s commitment to advancing outcomes for patients.   https://lnkd.in/exjYrybQ

With great pride and joy, I’d like to share a milestone moment we at #Pfizer have experienced in the last 12 hours. At the #ASCO24, we announced groundbreaking results from the 5-year follow up of our Phase 3 CROWN study for ALK+ advanced Non-Small Cell Lung Cancer (NSCLC). The study revealed that 60% of patients achieved 5 years of progression-free survival (PFS) with one of our treatments. In the words of the investigators and Lung Cancer experts, this is unprecedented. As highlighted in the Journal of Clinical Oncology (https://lnkd.in/gw35YHs5), ‘This is the longest PFS ever reported with any single-agent targeted treatment not only in advanced NSCLC but across all metastatic solid tumors’. The significant impact this can have on the quality of life for patients with ALK+ NSCLC and their families is truly humbling. At Pfizer, we are committed to bring breakthrough solutions in oncology and across therapeutic areas to help patients live better and longer lives. Read more at : https://lnkd.in/gJqBNsfW #PFEColleague #CancerResearch #LungCancer #letsoutdocancer 

BioSyngen has achieved a milestone with its pioneering #livercancer treatment, #BST02, receiving Fast Track Designation from #FDA. This designation, marks a pivotal moment in the fight against all types of #liver #cancer, including #hepatocellular #carcinoma and #cholangiocarcinoma. It represents an important step forward for liver cancer treatment, leveraging innovative adoptive #immune #celltherapy technology to offer new possibilities for patients. https://lnkd.in/dDN9R4FB

ECHO phase III trial of AstraZeneca’s Calquence combination regimen demonstrates significant and clinically meaningful improvement in PFS in 1st-line mantle cell lymphoma

There’s still considerable potential for TROP2 ADC development.